Great Novel Therapeutics Biotech & Medicals Corporation
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.
Founded Year
2013
Unified Business No.
54179426
Status
Active
Number of Employees
10
Total Paid-in
Capital
436,437,350 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2021)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Great Novel Therapeutics Biotech and Medicals Corporation (GNTbm) focuses on innovative oral new drug development for the treatment of advanced and refractory cancers. GNTbm is devoted to cancer immunotherapy, ranging from epigenetic modulators, tumor microenvironment regulators (TMRs) of new drug combinations, epigenetic immunoactivators, and immunoregulatory multi-kinase inhibitors, which can be applied to treat varieties of cancers and to meet the clinical needs of advanced and refractory cancers worldwide.
The main R&D core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunoactivator platform, and the immunoregulatory multiple-kinase inhibitor platform, are applied to the development of new drugs with innovative mechanisms in cancer immunotherapy. These oral innovative immune-regulating new drugs can activate the patient's immune system, remodel the tumor microenvironment, stimulate CTL to recognize and attack the tumor, and induce lasting immune memory, which can effectively improve the therapeutic benefits for patients with advanced and refractory cancers .
On the other hand, GNTbm has developed the new generation epigenetic modulator--- Tucidinostat (Chidamide) for the treatment of HR+/Her-2- advanced breast cancer, peripheral T-cell lymphoma, hepatocellular carcinoma (HCC) and other new cancers.
GNTbm independently develops new chemical entity (NCE) new drugs with innovative mechanisms and new drug combinations for cancer immunotherapy with better safety and superior efficacy, aiming at providing the unmet clinical needs of patients with advanced and refractory cancers.
The main R&D core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunoactivator platform, and the immunoregulatory multiple-kinase inhibitor platform, are applied to the development of new drugs with innovative mechanisms in cancer immunotherapy. These oral innovative immune-regulating new drugs can activate the patient's immune system, remodel the tumor microenvironment, stimulate CTL to recognize and attack the tumor, and induce lasting immune memory, which can effectively improve the therapeutic benefits for patients with advanced and refractory cancers .
On the other hand, GNTbm has developed the new generation epigenetic modulator--- Tucidinostat (Chidamide) for the treatment of HR+/Her-2- advanced breast cancer, peripheral T-cell lymphoma, hepatocellular carcinoma (HCC) and other new cancers.
GNTbm independently develops new chemical entity (NCE) new drugs with innovative mechanisms and new drug combinations for cancer immunotherapy with better safety and superior efficacy, aiming at providing the unmet clinical needs of patients with advanced and refractory cancers.
